Last reviewed · How we verify
NCT06870279
A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC
Phase 1 trial testing CGC738 in Advanced Clear Cell Renal Cell Carcinoma in 28 participants. Not yet recruiting.
1 August 2026
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 25 May 2025 |
| Primary completion | 1 August 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- CGC738 — full drug profile →
Conditions studied
- Advanced Clear Cell Renal Cell Carcinoma — all drugs for Advanced Clear Cell Renal Cell Carcinoma →
Sponsor
RenJi Hospital
Who can join
Adults 18 to 75, any sex, with Advanced Clear Cell Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced clear cell renal cell carcinoma (ccRCC).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Facts and Hopes of Chimeric Antigen Receptor-Redirected NK T Cells.
Courtney AN, Zhou X, Tian G, Wang Y, et al · · 2025 · cited 1× · PMID 41118265 · DOI 10.1158/1078-0432.ccr-25-0197 -
Innate immune cells in chimeric antigen receptor therapy.
Jassaud M, Ziane-Chaouche L, Duhamel M, Salzet M. · · 2026 · cited 1× · PMID 41058171 · DOI 10.1016/j.ymthe.2025.10.003 -
Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.
He W, McMichael AJ. · · 2026 · PMID 42027260 · DOI 10.1002/mco2.70742
Verify or expand the search:
- PubMed search for NCT06870279
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Clear Cell Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT07128680 — Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Met · Phase 1 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
- NCT06964958 — 177LuPSMA in Renal Cell Carcinoma · Phase 2 · active not recruiting
- NCT07000149 — A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for · Phase 3 · active not recruiting
- NCT07097935 — Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma · Phase 1, PHASE2 · recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06870279 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 24 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06870279.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing